Study in human cells shows it counteracts Ebola’s defenses
Amid the worsening Ebola outbreak in the Congo, now threatening to spill into Rwanda, a new study suggests that an existing, FDA-approved drug called nitazoxanide could potentially help contain this deadly, highly contagious infection. In meticulous experiments in human cells, led by Boston Children’s Hospital, the drug significantly amplified immune responses to Ebola and inhibited Ebola replication.
The study, published in the Cell Press journal iScience, also showed how the drug works: It enhances the immune system’s ability to detect Ebola, normally impeded by the virus.
Nitazoxanide, or NTZ, is currently used to treat gastrointestinal infections caused by parasites such as Giardia and Cryptosporidium. It has been shown to be safe and even comes in a formulation for children. Study leader Anne Goldfeld, MD, of the Program in Cellular and Molecular Medicine at Boston Children’s, hopes that, with further testing and validation, it could be part of the solution for Ebola.
“Currently, there is no easily deployable therapy for Ebola virus,” she says. “There are some very promising vaccines, but there is no oral, inexpensive medication available.”
The Ebola virus caused more than 10,000 deaths in the 2014-2016 West African epidemic and more than 1,800 lives (as of August 6th) in the current outbreak in the Democratic Republic of the Congo. The virus is very good at evading human immune defenses. Though very small, it has two genes devoted to blocking immune responses.
Goldfeld and collaborators Chad Mire, PhD and Thomas Geisbert, PhD at the University of Texas Medical Branch, Galveston, showed in Biosafety Level 4 laboratory experiments that NTZ inhibits the Ebola virus (isolated from an earlier outbreak). Additional experiments performed in collaboration with Sun Hur, PhD of Boston Children’s showed that NTZ works by broadly amplifying the interferon pathway and cellular viral sensors, including two known as RIG-I and PKR. By deleting RIG-I and PKR in human cells through CRISPR editing, Goldfeld and University of Texas colleagues showed that NTZ works through these molecules to inhibit Ebola virus.
“Ebola masks RIG-I and PKR, so that cells don’t perceive that Ebola is inside,” explains Goldfeld. “This lets Ebola get a foothold in the cell and race ahead of the immune response. What we’ve been able to do is enhance the host viral detection response with NTZ. It’s a new path in treating Ebola.”
Goldfeld hopes to move into animal studies soon, especially given that NTZ has already been used in millions of people with minimal side effects. If effective, it could thus be easily repurposed for Ebola treatment or prevention.
The Latest on: Ebola
via Google News
The Latest on: Ebola
- Map shows coronavirus' spread compared to SARS, swine flu and ebolaon February 23, 2020 at 4:37 pm
A new interactive map is highlighting how the current coronavirus outbreak compares to pandemics of the past. Updated daily based on the latest data from the World Health Organization, the Covid 2019 ...
- Warns It is Running Out of Money to Tackle Ebola Epidemic in DRCon February 23, 2020 at 9:13 am
GENEVA - The World Health Organization is urgently appealing for $40 million to salvage its operation to bring the Ebola epidemic to an end in eastern Democratic Republic of Congo. The Ebola operation ...
- Protecting midwives on the front lines of the Ebola responseon February 22, 2020 at 6:19 pm
NORTH KIVU AND ITURI PROVINCES, Democratic Republic of the Congo – The Democratic Republic of the Congo remains in the grip of the world’s second largest Ebola epidemic on record, although the ...
- Texas Justices Say Ebola Closure Suit Is Med Mal Claimon February 21, 2020 at 1:43 pm
Law360 (February 21, 2020, 4:37 PM EST) -- A bridal shop that permanently closed after a visit from an Ebola-infected nurse can't sue the hospital where the nurse worked, after the Texas Supreme Court ...
- How Ebola is helping the Democratic Republic of the Congo prepare for coronavirus diseaseon February 20, 2020 at 6:45 am
As the threat of coronavirus disease (COVID-19) looms over the Democratic Republic of the Congo (DRC), the expertise gained in fighting Ebola is helping public health authorities prepare for this new ...
- Ebola virus diseaseon February 20, 2020 at 1:28 am
Ebola virus disease (EVD) is a severe and frequently lethal disease caused by Ebola virus (EBOV). EVD outbreaks typically start from a single case of probable zoonotic transmission, followed by ...
- First Ebola, Now Coronavirus. Why an Omaha Hospital Gets the Toughest Cases.on February 18, 2020 at 3:11 pm
A biocontainment unit that drew attention for treating Ebola patients in 2014 is now evaluating more than a dozen cruise ship evacuees for the coronavirus. A convoy transported Americans who had been ...
- Overcoming the fear of Ebola in marginalized communitieson February 18, 2020 at 9:25 am
Reaching out to all communities is vital for Ebola prevention. The Batwa people in the Democratic Republic of the Congo are hunter-gatherers, who move around frequently and live in temporary camps in ...
- Researchers show how Ebola virus hijacks host lipidson February 18, 2020 at 9:04 am
Robert Stahelin studies some of the world's deadliest viruses. Filoviruses, including Ebola virus and Marburg virus, cause viral hemorrhagic fever with high fatality rates. Stahelin, professor at ...
- Coronavirus quarantine: American doctor who survived Ebola shares experienceon February 18, 2020 at 8:32 am
The coronavirus outbreak is an opportunity to "choose compassion over fear," Ebola survivor Dr. Kent Brantly told FOX Business in an exclusive interview. Continue Reading Below Brantly contracted the ...
via Bing News